173901-02-5

Basic information

• Product Name: Benzenesulfonyl chloride, 4-[[(hexylamino)carbonyl]amino]-
• CAS NO: 173901-02-5
• Molecular Formula: C13H19ClN2O3S
• Molecular Weight: 318.824
• Mol File: 173901-02-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenesulfonyl chloride, 4-[[(hexylamino)carbonyl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonyl chloride, 4-[[(hexylamino)carbonyl]amino]-(173901-02-5)
• EPA Substance Registry System: Benzenesulfonyl chloride, 4-[[(hexylamino)carbonyl]amino]-(173901-02-5)

Safety Data

• Hazardous Substances Data: 173901-02-5(Hazardous Substances Data)

Upstream product

• 1142-07-0 1-n-hexyl-3-phenyl-urea 
• 111-26-2 hexan-1-amine 
• 62-53-3 aniline 
• 106-32-1 octanoic acid ethyl ester 
• 6752-38-1 4-chlorosulfonylbenzene isocyanate 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 173901-20-7 (2-{4-[4-(3-Hexyl-ureido)-benzenesulfonylamino]-phenyl}-ethyl)-((R)-2-hydroxy-2-pyridin-3-yl-ethyl)-carbamic acid tert-butyl ester 
• 241467-59-4 1-{4'-[4-(3-hexyl-ureido)-benzenesulfonylamino]-biphenyl-4-yloxymethyl}-6,7-dihydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 241467-61-8 N-[2-(3,4-bis-benzyloxy-phenyl)-ethyl]-2-{6-[4-(3-hexyl-ureido)-benzenesulfonylamino]-naphthalen-2-yloxy}-acetamide 
• 373359-54-7 4-(3-hexylureido)-N-[4-(4-oxopiperidin-1-yl)phenyl]benzenesulfonamide 
• 392231-84-4 1-hexyl-3-[4-(4-oxo-piperidine-1-sulfonyl)-phenyl]-urea 

Relevant articles and documents

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Substituted sulfonamides are selective β 3 adrenergic receptor agonists with very little β 1 and β 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent